<SEC-DOCUMENT>0001564590-21-010650.txt : 20210304
<SEC-HEADER>0001564590-21-010650.hdr.sgml : 20210304
<ACCEPTANCE-DATETIME>20210303190320
ACCESSION NUMBER:		0001564590-21-010650
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		8
CONFORMED PERIOD OF REPORT:	20210303
FILED AS OF DATE:		20210304
DATE AS OF CHANGE:		20210303

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioNTech SE
		CENTRAL INDEX KEY:			0001776985
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			2M
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39081
		FILM NUMBER:		21711494

	BUSINESS ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
		BUSINESS PHONE:		0049613190847081

	MAIL ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>bntx-6k_20210303.htm
<DESCRIPTION>6-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-6k_20210303.DOCX.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:20pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549<font style="font-weight:normal;color:#000000;"> </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:20pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gg3ydf13vmxa000001.jpg" title="" alt="" style="width:169px;height:0px;"><br /><font style="font-weight:bold;">FORM 6-K</font> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gg3ydf13vmxa000002.jpg" title="" alt="" style="width:169px;height:0px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a&#8209;16 OR 15d&#8209;16<font style="font-weight:normal;color:#000000;"> </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNDER THE SECURITIES EXCHANGE ACT OF 1934<font style="font-weight:normal;color:#000000;"> </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FOR THE MONTH OF MARCH 2021<font style="font-weight:normal;color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gg3ydf13vmxa000003.jpg" title="" alt="" style="width:169px;height:0px;"></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COMMISSION FILE NUMBER 001-39081 </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BioNTech SE<br /><font style="color:#333333;font-size:10pt;font-weight:normal;">(Translation of registrant&#8217;s name into English)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">An der Goldgrube 12</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">D-55131 Mainz</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Germany</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">+49 6131-9084-0<br /><font style="color:#333333;font-size:10pt;font-weight:normal;">(Address of principal executive offices)</font><font style="font-weight:normal;color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gg3ydf13vmxa000004.jpg" title="" alt="" style="width:169px;height:0px;"></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20&#8209;F or Form 40&#8209;F:<font style="color:#000000;"> </font>Form 20&#8209;F <font style="font-family:Segoe UI Symbol;">&#9746;</font> Form 40&#8209;F <font style="font-family:Segoe UI Symbol;">&#9744;</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(1):<font style="color:#000000;"> </font><font style="font-family:Segoe UI Symbol;">&#9744;</font> </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(7)<font style="color:#000000;">: </font><font style="font-family:Segoe UI Symbol;">&#9744;</font> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;">DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 3, 2021, BioNTech SE (the &#8220;Company&#8221;) and Pfizer Inc. announced the arrival of the first doses of their COVID-19 vaccine in Rwanda through the COVAX Facility. The press release is attached hereto as Exhibit 99.1.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:14pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;">SIGNATURE</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.14%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<font style="color:#000000;"> </font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50.63%;"></td>
<td style="width:4.63%;"></td>
<td style="width:44.73%;"></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">BioNTech SE</p></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-Top:0pt; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Dr. Sierk Poetting</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt; border-top:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Dr. Sierk Poetting</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&nbsp;&nbsp; Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 3, 2021 </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;">EXHIBIT INDEX </font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:10.98%;"></td>
<td style="width:89.02%;"></td>
</tr>
<tr style="height:1pt;">
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit</font></p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Description of Exhibit</font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bntx-ex991_7.htm"><font style="text-decoration:underline;">Pfizer-BioNTech&#8217;s COVID-19 Vaccine Arrives in Rwanda.</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>bntx-ex991_7.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-ex991_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:49.97%;"></td>
<td style="width:50.03%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpcy5u2kahak000001.jpg" title="" alt="" style="width:169px;height:68px;"></p></td>
<td valign="middle" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpcy5u2kahak000002.jpg" title="" alt="" style="width:240px;height:26px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Pfizer-BioNTech&#8217;s COVID-19 Vaccine Arrives in Rwanda</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:14pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:3.98%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">First mRNA vaccine doses delivered to the African continent will be used <br />to vaccinate at-risk, front-line healthcare workers</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:3.98%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">NEW YORK and MAINZ, GERMANY, March 3, 2021<font style="font-weight:normal;"> - </font><font style="text-decoration:underline;font-weight:normal;">Pfizer Inc.</font><font style="font-weight:normal;"> (NYSE: PFE) and </font><font style="text-decoration:underline;font-weight:normal;">BioNTech SE</font><font style="font-weight:normal;"> (Nasdaq: BNTX), in partnership with </font><font style="text-decoration:underline;font-weight:normal;">UNICEF</font><font style="font-weight:normal;">, today announced the arrival of the first doses of their COVID-19 vaccine in Rwanda through the COVAX Facility.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This is the companies&#8217; first delivery to a COVAX Advanced Market Commitment (AMC) country of their mRNA vaccine. The almost 103,000 doses will be used to vaccinate at-risk, front-line healthcare workers across the country.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.98%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;These are the first doses of an mRNA vaccine to arrive on the African continent &#8211; an important milestone for the region, for Rwanda, and for the global health partners working tirelessly to fight this pandemic,&#8221; said Janine Small, Pfizer Global President for Emerging Markets. &#8220;The delivery of these doses and the subsequent vaccinations demonstrate that global partners can work together to create the conditions that ensure developing countries can benefit from a new generation of vaccines. We will continue to work closely with COVAX,&#8239;its partners,&#8239;and the countries receiving doses of our vaccine&#8239;to achieve our shared goal of securing equitable access for COVID-19 vaccines for all people around the world.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;SARS-CoV-2 does not differentiate between borders &#8211; a global pandemic requires comprehensive solutions and worldwide collaborations between companies, governments and global institutions. Our goal is to make vaccines accessible worldwide and today&#8217;s delivery to Rwanda is a great step forward. We will continue to work with COVAX to make COVID-19 vaccines available in many more low- and lower-middle-income countries and help protect vulnerable people worldwide,&#8221; said Ugur Sahin, M.D., CEO and Co-founder of&#160;BioNTech. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer and BioNTech have already supplied doses through COVAX to South Korea and Colombia and will continue supplying doses to a number of diverse economies in all regions of the world, including a number of low and lower-middle income countries, as part of the up to 40 million doses the companies have committed to the Facility through 2021.&nbsp;&nbsp; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The vaccine, which is based on BioNTech&#8217;s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorizations Holder in the European Union, and the holder of emergency use authorizations or equivalent in the United States, United Kingdom, Canada and other countries in advance of a planned application for full marketing authorizations in these countries.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">AUTHORIZED USE: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Pfizer-BioNTech COVID19 vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564 (b) (1) of the FD&amp;C Act unless the declaration is terminated or authorization revoked sooner. </p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.96%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Full EUA Prescribing Information available at </font><font style="text-decoration:underline;color:#000000;">www.cvdvaccine.com</font><font style="color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">IMPORTANT SAFETY INFORMATION: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Do not administer Pfizer-BioNTech COVID-19 vaccine to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Pfizer-BioNTech COVID-19 vaccine. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer- BioNTech COVID-19 vaccine. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Monitor Pfizer-BioNTech COVID-19 vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (</font><font style="font-size:10pt;text-decoration:underline;color:#000000;">https://www.cdc.gov/vaccines/covid-19/</font><font style="font-size:10pt;">). </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 vaccine. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">The Pfizer-BioNTech COVID-19 vaccine may not protect all vaccine recipients. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">In clinical studies, adverse reactions in participants 16 years of age and older included pain at the injection site (84.1%), fatigue (62.9%), headache (55.1%), muscle pain (38.3%), chills (31.9%), joint pain (23.6%), fever (14.2%), injection site swelling (10.5%), injection site redness (9.5%), nausea (1.1%), malaise (0.5%), and lymphadenopathy (0.3%). </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Severe allergic reactions, including anaphylaxis, have been reported following the Pfizer-BioNTech COVID-19 vaccine during mass vaccination outside of clinical trials. Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Pfizer-BioNTech COVID-19 vaccine. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Available data on Pfizer-BioNTech COVID-19 vaccine administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Data are not available to assess the effects of Pfizer-BioNTech COVID-19 vaccine on the breastfed infant or on milk production/excretion. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">There are no data available on the interchangeability of the Pfizer-BioNTech COVID-19 vaccine with other COVID-19 vaccines to complete the vaccination series. Individuals who have received one dose of Pfizer-BioNTech COVID-19 vaccine should receive a second dose of Pfizer-BioNTech COVID-19 vaccine to complete the vaccination series. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Vaccination providers must report Adverse Events in accordance with the Fact Sheet to VAERS at http s://vaers.hhs.gov/reportevent.html or by calling 1-800-822-7967. The reports should include the words "Pfizer-BioNTech COVID-19 vaccine EUA" in the description section of the report. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Vaccination providers should review the Fact Sheet for Information to Provide to vaccine Recipients/Caregivers and Mandatory Requirements for Pfizer-BioNTech COVID-19 vaccine Administration Under Emergency Use Authorization. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) including Full EUA Prescribing Information available at <font style="text-decoration:underline;">www.cvdvaccine-us.com</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.96%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">About Pfizer: Breakthroughs That Change Patients&#8217; Lives</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at <font style="text-decoration:underline;color:#0563C1;">www.Pfizer.com</font>. In addition, to learn more, please visit us on <font style="text-decoration:underline;color:#0563C1;">www.Pfizer.com</font> and follow us on Twitter at <font style="text-decoration:underline;">@Pfizer</font> and <font style="text-decoration:underline;">@Pfizer News</font>, <font style="text-decoration:underline;">LinkedIn</font>, <font style="text-decoration:underline;">YouTube</font> and like us on Facebook at <font style="text-decoration:underline;">Facebook.com/Pfizer</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">About BioNTech </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit <font style="text-decoration:underline;">www.BioNTech.de</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.96%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Forward-looking Statements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release contains &#8220;forward-looking statements&#8221; of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech&#8217;s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer regarding a COVID-19 vaccine; our expectations regarding the potential characteristics of BNT162b2 in our Phase 2/3 trial and/or in commercial use based on data observations to date, including real-world data gathered; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on trial data of BNT162b2 in our Phase 2/3 trial; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and, if approved, market demand, including our production estimate for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For a discussion of these and other risks and uncertainties, see BioNTech&#8217;s Quarterly Report for the Three and Nine Months Ended September 30, 2020, filed as Exhibit 99.2 to its Current Report on Form 6-K filed with the SEC on November 10, which is available on the SEC&#8217;s website at <font style="text-decoration:underline;color:#000000;">www.sec.gov</font>. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Contacts: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Media Relations </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sharon J. Castillo&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+1 (202) 494-6769 </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Sharon.Castillo@Pfizer.com</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investor Relations </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chuck Triano </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+1 (212) 733-3901 </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Charles.E.Triano@Pfizer.com</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Contacts: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Media Relations </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jasmina Alatovic </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+49 (0)6131 9084 1513 </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Media@biontech.de</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investor Relations </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sylke Maas, Ph.D. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+49 (0)6131 9084 1074 </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Investors@biontech.de</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gg3ydf13vmxa000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gg3ydf13vmxa000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ! A(# 2(  A$! Q$!_\0
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/3_T;%110!]/T444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gpcy5u2kahak000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpcy5u2kahak000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !3 NX# 2(  A$! Q$!_\0
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M_2?]\FNS^S,7_)^*_P Q71@9/K1D^M;_ /PBLO\ S])_WR:/^$5E_P"?I/\
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MH **** "BBB@#PKQ"Q_X274^3_Q]2=_]HU7L&;SVY/W?7W%6/$7_ ",NJ?\
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MCV'L*UZ**9[<8J*M$****"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#PKQ%_R,NJ?]?4G_H1JOI_^O;_ '?ZBK'B+_D9=4_Z^I/_ $(U
M7T__ %[?[O\ 45)\]+^(_4Z8_$C6PQ'EV?7_ )YM_P#%4G_"R=;_ .>5D?\
MMFW_ ,57(-]X_6I;>TN;QBMM;S3LHR1$A8@?A3+^L5GM)G5_\+)UO_GC9?\
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MH?0_SH*PT:4I_O'J=H %    '  I:**9[9X=XI_Y&G4O^N[5;\#?\CA8_P#
M_P#T!JJ>*?\ D:=2_P"N[5;\#?\ (X6/_ __ $!J1X,?]X7K^I[-7,^/I"GA
M&Z _C=%_\>!_I735RWQ!4GPE,?21#^M,]FO_  I>AY!7K?PY@$7A?S .99W8
M_A@?TKR2O7_AZX?PG$H_@E=3^>?ZTD>7@/XOR.IHHHIGLA1110 4444 %%%%
M 'E7Q*@$?B&"4#_6VXS]02/Y8KCXG,<J..JL"*[7XFN#K5G'W6WR?Q8_X5Q
MY('O2/!Q.E:5CZ&!W*".XS0WW&^E(@Q&H/8 4K?<;Z4/8]X\XKH/"O\ Q\7'
M^X/YUS]=!X5_X^+C_<'\Z^,RS_>X?UT+>QU%1S0QW$312H'1AR#4E%?9M)JS
M(.+U;1Y-/?S$R]N3PW=?8UEUZ.Z+(A1U#*PP01P:Y/6-#:TW3VP+0=2O=/\
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M4?\ "R-;_P">=G_W[;_XJN>_L35O^@7>_P#@._\ A1_8FK?] N]_\!W_ ,*
M]M7[LZ'_ (61K?\ SSL_^_;?_%4?\+(UO_GG9_\ ?MO_ (JN>_L35O\ H%WO
M_@._^%']B:M_T"[W_P !W_PH#VU?NSH?^%D:W_SSL_\ OVW_ ,51_P +(UO_
M )YV?_?MO_BJY[^Q-6_Z!=[_ . [_P"%']B:M_T"[W_P'?\ PH#VU?NSH?\
MA9&M_P#/.S_[]M_\51_PLC6_^>=G_P!^V_\ BJY[^Q-6_P"@7>_^ [_X4?V)
MJW_0+O?_  '?_"@/;5^[.A_X61K?_/.S_P"_;?\ Q5=EX,U^\U^QN9KQ8@T<
M@5?+4@8QGN37EG]B:M_T"[W_ ,!W_P *]%^'-G<V>F7BW5O- S3 @2H5)&/>
M@Z<+4JRJI2;L=I7F'Q.D)UBRC[+;[OS8_P"%>GUY;\35QKMJWK; ?^/-0SIQ
MO\%G% ;F '<XKZ"MX5M[:*%1A8T"#Z 8KY^0[75O0YKZ%5@RAAT(R*$<^7?:
M^0M%%%,],**** "BBB@ HHHH **** "N6\:>(;WP_!:/9K"3,S!O,4GH!Z$>
MM=37 ?%#_CTTW_??^0H,,3)QI-HQO^%D:W_SSL_^_;?_ !5'_"R-;_YYV?\
MW[;_ .*KCZN)I&I2(KII]VRL,JRPL01^5(\A8BL]FSI/^%D:W_SSL_\ OVW_
M ,51_P +(UO_ )YV?_?MO_BJYW^QM5_Z!MY_WX;_  H_L;5?^@;>?]^&_P *
M!^VK]V=%_P +(UO_ )YV?_?MO_BJ/^%D:W_SSL_^_;?_ !5<[_8VJ_\ 0-O/
M^_#?X4?V-JO_ $#;S_OPW^% >VK]V=%_PLC6_P#GG9_]^V_^*H_X61K?_/.S
M_P"_;?\ Q5<[_8VJ_P#0-O/^_#?X4?V-JO\ T#;S_OPW^% >VK]V=%_PLC6_
M^>=G_P!^V_\ BJ/^%DZW_P \K/\ []M_\57._P!C:K_T#;S_ +\-_A1_8VJ_
M] V\_P"_#?X4![:OW9!>74E]>SW<H4232-(P4<9)R<5)I_\ KV_W?ZBJSH\4
MC1R(R.IPRL,$'T(JSI_^O;_=_J*1BK\VI5;[Q^M=Q\,?^0O>_P#7 ?\ H0KA
MV^\?K7<?#'_D+WO_ %P'_H0IFV%_C1/3Z***9[H4444 %%%% !1U&#110!Y?
M\0M M]/F@U&TC6..=BDB*, /U!'U&?RKB 2"""01R"*]1^)DJ+H5K$3\[W(8
M#V"G/\Q7EM)GAXR*C5=CW7P]>OJ/A^QNI3F22(;SZD<$_I6G6%X-_P"11T[_
M *YG_P!"-;M,]FDVX)OL>'>*?^1IU+_KNU6_ W_(X6/_  /_ - :JGBG_D:=
M2_Z[M5OP-_R.%C_P/_T!J1XD?]X7K^I[-6'XPMS<^$]00#)6,2?]\D-_2MRF
M31)/!)#(,I(I5AZ@C!IGN3CS1<>Y\]5Z-\,M07RKS36;#!A.@]>S?R6N"U"R
MDT[4;BSE'SPN4/OZ'\1S3]+U*?2=2AO;<_O(FS@]&'<'V(I'A4:CI5$V>^45
MFZ+K=GKEDMQ:N,X_>1D_,A]#_C6E3/>C)25T%%%% PHHHH ***Y/QCXLBTBU
MDL[20-J$@Q\I_P!4#W/OZ"@BI4C3CS2."\9Z@NH^*+IT;,<1$*'_ '>OZYK+
MTJW-WJ]G;@9\R9%_,BJG4Y-=;\/=--YXA^U,N8K1"Y/^T> /YG\*1X<;U:OJ
MSUND;[C?2EI&^XWTH>Q[YYQ70>%?^/BX_P!P?SKGZZ#PK_Q\7'^X/YU\9EG^
M]P_KH6]CJ****^T("CJ,&BB@#F=8T';NN;-?EZO$.WN/\*YVO2*P=8T(3[KB
MT4"7JR#HWT]Z^?S'*KWJT%ZK_+_(I,PM-U.;3IMR?-&?OH3P?_KUVEI>0WL
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M^1IU+_KNU6_ W_(X6/\ P/\ ] :JGBG_ )&G4O\ KNU6_ W_ ".%C_P/_P!
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M5?<'_"%>'?\ H&)_W\?_ !H_X0KP[_T#$_[^/_C110'L:?\ *ON#_A"O#O\
MT#$_[^/_ (U>TW0=,TB5Y+"T6%W&UB&8Y'XFBB@:I03NDC1JCJ6CZ?JZQK?V
MPF6,DH"Q&,]>AHHH*:35F9W_  A7AW_H&)_W\?\ QK<AACMX(X8EVQQJ$1?0
M#@444"C",?A5A]%%%!04444 %%%% !1110!BS^$M"NKB2XFT]'EE8N[;VY)Y
<)ZTU/!V@1ME-.0'&/OO_ (T44&?LJ>_*ON/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>gg3ydf13vmxa000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gg3ydf13vmxa000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ! A(# 2(  A$! Q$!_\0
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/3_T;%110!]/T444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>gpcy5u2kahak000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpcy5u2kahak000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #6 A(# 2(  A$! Q$!_\0
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M!&0:^:OC7X*MO#NM6^K:="L5EJ!;?$@PL<HY./0$'./8U]*UY-^T"8_^$(L
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M250BA5 "@8 ':EHR*,BOS [0HHR*,B@ HHHH **,BC(H **,BC(H **,BC-
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M>Y?D?^.[1^%?+>B:9)K.NV&F1YW75PD(([;B 3^%?:T,*6\$<,2A8XU"*H[
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M_P ")?\ XJA\281[PE]R_P P]C(^6/[3O_\ G^N?^_K?XT?VG?\ _/\ 7/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% "'.#@X/8UXS/^S[:W-Q+/+XDN6DE<N[&V7DDY)^]1175AL;7PM_8RM?T
M)<5+<C_X9VLO^ABN/_ 9?_BJ[?P!\.[3P%'?>3>O>2W93=(\83:%S@#!/J:*
M*UKYIBZ\'3J3NGZ?Y H13NCM****X"@HHHH **** "BBB@ HHHH **** "BB
HB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>gg3ydf13vmxa000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gg3ydf13vmxa000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ! A(# 2(  A$! Q$!_\0
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/3_T;%110!]/T444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>gg3ydf13vmxa000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gg3ydf13vmxa000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ! A(# 2(  A$! Q$!_\0
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/3_T;%110!]/T444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
